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We describe a gold nanoparticle-based sandwich immunoassay for the dual detection and measurement
of hemoglobin A1c (HbA1c) and total hemoglobin in the whole blood (without pretreatment) in a single
step for personalized medicine. The optimized antibody-functionalized gold nanoparticles immunoreact
simultaneously with HbA1c and total hemoglobin to form a sandwich at distinctive test lines to trans-
duce visible signals. The applicability of this method as a personal management tool was demonstrated
by establishing a calibration curve to relate % HbA1c, a useful value for type 2 diabetes management, to
the signal ratio of captured HbA1c to all other forms of hemoglobin. The platform showed excellent
selectivity (100%) toward HbA1c at distinctive test lines when challenged with HbA0, glycated HbA0 and
HbA2. The reproducibility of the measurement was good (6.02%) owing to the dual measurement of
HbA1c and total hemoglobin. A blood sample stability test revealed that the quantitative measurement of
% HbA1c was consistent and no false-positive results were detected. Also, this method distinguished the
blood sample with elevated HbF from the normal samples and the variants. The ﬁndings of this study
highlight the potential of a lateral ﬂow immunosensor as a simple, inexpensive, consistent, and con-
venient strategy for the dual measurement of HbA1c and total Hb to provide useful % HbA1c values for
better on-site diabetes care.1. Introduction
Hemoglobin A1c (HbA1c) plays a central role in the diagnosis
and monitoring of type 2 diabetes. A current report from the WHO
estimates that 80% of global type 2 diabetes-related deaths occur
in low- and middle-income countries (WHO, 2015) in which the
market for HbA1c tests is limited by the scarcity of the resources.
In these countries, inexpensive HbA1c monitoring tools for per-
sonalized medicine are crucial in the provision of in-time treat-
ments that slow disease progression and minimize devastating
health, social, and economic burdens in afﬂicted individuals. The
development of inexpensive, user-friendly methods for HbA1c
testing reduces implementation costs, increases public access to
HbA1c test, and improves disease management through by mon-
itoring the % HbA1c.
Ion-exchange high-performance liquid chromatography (HPLC)r).
5and afﬁnity chromatography are generally used to perform HbA1c
tests, but the long turnaround time and high implementation cost
are incompatible with on-site disease management. Although
commercially available point-of-care devices are designed to be
mobile for on-site use, their implementation costs limit the use in
underdeveloped countries.
The demand for relatively inexpensive point-of-care devices for
HbA1c measurement in resource-limited regions has driven on-
going attempts to develop more rapid, consistent, easy-to-use, and
cost-effective biosensors for HbA1c measurement. Compared with
various HbA1c biosensors such as microarrays (Chen et al., 2012),
surface plasmon resonance (Liu et al., 2008), and chemilumines-
cence ﬂow cells (Ahn et al., 2016), electrochemical biosensors are
highly favored for HbA1c detection (Xue et al., 2011; Song and
Yoon, 2009; Hsieh et al., 2013) because of their compatibility with
miniaturization into portable point-of-care devices (Liu et al.,
2012). However, the multiple steps of results interpretation and
measurement that require professional personnel increase the
implementation costs of this method. Such limitations have driven
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materials (e.g., paper) to provide simple, rapid, on-site results.
Although lateral ﬂow assays are commonly designed to per-
form qualitative detection in which an on/off signal is sufﬁcient
(Posthuma-Trumpie et al., 2008), the invention of reﬂectance
readers has made it possible to measure the signal transduced on
the paper-based platform, which allows the quantitation of target
analytes with lateral ﬂow strips. Aimed at reducing the cost of
HbA1c tests to cater to the needs of patients in underdeveloped
regions, two lateral ﬂow strip designs for the detection and mea-
surement of HbA1c have been reported (McCroskey and Melton,
2010; Sundrehagen, 2014). Although these designs could cater to
the demand for low-cost HbA1c assays, their testing procedures,
which involve either a two-step measurement or an elaborate
pretreatment of whole blood before testing, still require profes-
sional personnel.
In this study, the drawbacks of previously reported HbA1c
lateral ﬂow strip designs are addressed with the development of a
lateral ﬂow immunosensor that directly detects both total Hb and
HbA1c in human whole blood without sample pretreatment. The
dual-detection design of the immunosensor substantially sim-
pliﬁes the workﬂow and allows interpretation and measurement
to be performed in a single step. Compared with previously re-
ported lateral ﬂow assays that use biomimetic boronate groups,
which can bind to all of the glycan moieties that readily coexist
with HbA1c in whole blood, sandwich immunoassays are re-
portedly more selective and sensitive in probes for multi-epitope
antigens such as Hb (Ngom et al., 2010). In addition to being more
selective than the previously reported lateral ﬂow assays, when
compared to platforms that measure only absolute % HbA1c
(Chuang et al., 2012), this lateral ﬂow immunosensor that mea-
sures both HbA1c and total Hb not only allows more stable esti-
mation of % HbA1c by compensating for intra- and inter-variation
in total Hb but is also particularly useful in patients with sickle cell
anemia, in which the amount of Hb is decreased. For these pa-
tients, the dual detection of HbA1c and total Hb is helpful in dis-
tinguishing true-negative from false-negative results because the
HbA1c levels can be falsely low when only absolute % HbA1c is
measured. The successful incorporation of a dual-detection tech-
nology in a simple, user-friendly, and inexpensive platform pro-
motes efforts to improve the accessibility of HbA1c tests, parti-
cularly in remote settings.2. Materials and methods
2.1. Chemicals and materials
Naked gold nanoparticles (40 nm) were purchased from Kestrel
Biosciences Co., Ltd. (Pathumthani, Thailand), and bovine serum
albumin was purchased from Amresco LLC (Solon, OH, USA).
Western blocking reagent (10%) was obtained from Roche Diag-
nostics (Selangor, Malaysia). Anti-HbA1c antibody (monoclonal,
IgG1), anti-Hb antibody (polyclonal, goat), rabbit anti-goat poly-
clonal antibody, puriﬁed HbA1c, HbA0, glycated HbA0, and HbA2
were purchased from Fitzgerald Industries International (Acton,
MA, USA). Hemolysis reagent was purchased from Kamiya Bio-
medical Company (Seattle, WA, USA). All other chemicals were
purchased from Sigma-Aldrich (Selangor, Malaysia). Phosphate
buffer (pH 7.4) was prepared with Na2HPO4 and NaH2PO4, and
NaCl, K2CO3, and HCl were prepared with Milli-Q water with a
resistivity of 18.2 MΩ cm. Antibodies and puriﬁed HbA1c, HbA0,
and glycated species of HbA0 and HbA2 were diluted with phos-
phate buffer. Laminated nitrocellulose (NC) membrane cards (ref.
HF135MC100), cellulose ﬁber pads (ref. CFSP173000), and glass
ﬁber pads (ref. GFCP083000) were acquired from Merck Millipore(Selangor, Malaysia). Blood samples were collected from the Uni-
versity of Malaya Medical Center (UMMC), and informed consent
was obtained from the patients recruited. The study protocol was
implemented in accordance with the policies of the institutional
medical ethics board committee.
2.2. Apparatus
Test strips were cut by using a Matric 2360 programmable
shear from Kinematic Automation (Sonora, CA, USA). An Inﬁnites
M200 PRO microplate reader (Tecan Group Ltd., Männedorf,
Switzerland) was used to measure the absorbance of the gold
conjugates (at 530 nm). An ESEQuant lateral ﬂow reader (Qiagen
Lake Constance GmbH, Stockach, Germany) was used for quanti-
tative measurement of the signal on the immunosensor.
2.3. Conjugation of detecting antibody to gold nanoparticles
Gold conjugates were prepared with 10 mL colloidal gold na-
noparticles adjusted to pH 8.0 and polyclonal anti-Hb antibody at a
ﬁnal concentration of 30.0 μg mL1. The gold conjugates were
incubated for 1 h with gentle shaking (100 rpm) at room tem-
perature. Next, bovine serum albumin at a ﬁnal concentration of
1% (w/v) was added to the gold conjugates and allowed to shake
for an additional hour. The gold conjugates were centrifuged at
11627g for 30 min at 4 °C to yield a soft pellet, which was then
resuspended in 10 mM phosphate buffer containing 1% (w/v) bo-
vine serum albumin. The conjugates were stored at 4 °C until use.
2.4. Construction of the HbA1c lateral ﬂow immunosensor
The lateral ﬂow immunosensor was composed of a buffer ap-
plication pad, conjugate pad, laminated NC membrane, and ab-
sorbent pad (Scheme 1) and comprised ﬁve lines: three HbA1c test
lines coated with anti-HbA1c antibody (monoclonal, IgG1), one Hb
line on which anti-Hb antibody (polyclonal, goat) was im-
mobilized, and one control line coated with secondary polyclonal
rabbit anti-goat antibody. The antibodies were lined manually
with a pipette. After lining, the strips were dried in a desiccator for
30 min. Later, they were blocked with 1% (w/v) western blocking
reagent in 10 mM phosphate buffer. The gold-conjugated poly-
clonal anti-Hb antibody (detecting antibody) prepared in 10 mM
phosphate buffer supplemented with 10% (w/v) sucrose were de-
posited onto the glass ﬁber conjugate pad to dry overnight in a
desiccator. The full lateral ﬂow immunosensor was then as-
sembled with the cut buffer application pad, dried conjugate pad,
and laminated NC membrane with an absorbent pad (4-mm
width). Overlap between the conjugate pad and NC membrane
was optimized at 1 mm, whereas the NC membrane and absorbent
pad overlapped at 2 mm.
2.5. Optimization of the detection format for the sandwich
immunoassay
To develop a functional sandwich immunoassay that could
detect total Hb and HbA1c simultaneously, we used two formats:
one with the Hb line ﬁrst (closest to the conjugate pad) and one
with the Hb line toward the end of the strip (closest to the control
line). The two formats were tested with three blood samples with
different % HbA1c values (5.3%, 6.5%, and 9.0% HbA1c, diluted 1:5
with hemolysis reagent). After depositing the diluted blood onto
the NC membrane, we added washing buffer to complete the as-
say. Patterns were then observed to determine the ideal detection
format for the sandwich immunoassay. The results from quanti-
tative analysis (determined by an ESEQuant lateral ﬂow reader) for
these two formats were presented in Table S1, Supplementary
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Scheme 1. Schematic representation of simultaneous detection of HbA1c and hemoglobin using sandwich immunoassay on lateral ﬂow strip.
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2.6. Selectivity test
The assembled HbA1c immunosensor was tested with puriﬁed
HbA0, HbA1c, glycated HbA0 and HbA2. All puriﬁed reagents were
prepared in 10 mM phosphate buffer to a ﬁnal concentration of
0.1 mg mL1. The immunosensor was tested in triplicate with
10 μL diluted puriﬁed antigen. After the puriﬁed antigen was
dispensed, the assay was completed with the addition of washing
buffer (50 mM phosphate buffer containing Tween-20) and the
signal generated on the strips was measured with the ESEQuant
lateral ﬂow reader.
2.7. Investigation of the interference by variants
Three variant blood samples, HbE, HbJ, and HbH, were collected
with the anticoagulant ethylenediaminetetraacetic acid and ver-
iﬁed with a Bio-Rad Variant II HPLC (Hercules, CA, USA). These
samples were collected from the hematology lab and tested on the
seventh day after withdrawal from patients or donors. A blood
sample with elevated HbF was discovered incidentally during the
study and was tested on the same day it was withdrawn from the
patient. All four samples (three variants and the elevated HbF
sample) were diluted 1:5 with hemolysis reagent before testing.
The signals were measured with the lateral ﬂow reader.
2.8. Determination of the effects of long storage on the analysis
Over 7 days, one blood sample with 6% HbA1c was tested on
the fabricated strips. Throughout the study, the sample was di-
luted 1:5 with hemolysis reagent. The diluted sample was dis-
pensed directly onto the NC membrane. Later, the strips (tripli-
cates for each point of testing) were washed with 50 mM phos-
phate buffer containing Tween-20. The signals generated on the
strips were measured with the lateral ﬂow reader. A two-tailed t-
test was performed to determine the signiﬁcance of the difference
in signals observed over 7 days.2.9. Reproducibility study
Nine lateral ﬂow immunosensors were tested with a diluted
blood sample of 5.0% HbA1c (determined with the Bio-Rad Variant
II HPLC). Blood samples were diluted 1:5 with hemolysis reagent
(distilled water with blood stabilizers) before testing, and washing
buffer was added to complete the assay. Signals were measured
with the ESEQuant lateral ﬂow reader.
2.10. Generation of the calibration curve
The calibration curve was generated based on the HbA1c/total Hb
ratio as a function of % HbA1c. To factor in all pre-existing interfering
agents in whole blood, we established the calibration curve with
whole blood samples collected from UMMC. The signal intensities for
the test and Hb lines were measured for each % HbA1c sample col-
lected and the ratio was calculated. All whole blood samples were
diluted with the hemolysis reagent before testing. The signals gen-
erated were measured with the ESEQuant lateral ﬂow reader.3. Results and discussion
3.1. Dual-detection strategy
Scheme 1 is a schematic illustration of single-step dual detec-
tion of HbA1c and total Hb on the same sensing platform. This
lateral ﬂow test strip was designed with an Hb line, three test lines
for the speciﬁc detection of HbA1c, and a control line (ﬁve lines
total) for simultaneous detection of HbA1c and total Hb. Antibody-
functionalized gold nanoparticles were optimized to perform
sandwich immunoreaction at test lines 1–3 and the Hb line, the
results of which were transduced into a visible signal on the strip.
The transduced signal was read semi-quantitatively with the
naked eye and measured quantitatively with a lateral ﬂow reader.
With the transduced immunoreactions occurring at distinctive
lines after detecting HbA1c and Hb, the reported lateral ﬂow im-
munosensor provided the ratio of HbA1c to total Hb, which is
particularly useful for the measurement of % HbA1c.
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Fig. 1. (A) Designs of the Type 1 and Type 2 detection format, with the Hb line positioned either before or after the three HbA1c test lines. (B) Whole blood testing with
increasing % HbA1c using the type 1 and type 2 design.
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immunoassay
Fig. 1a illustrates the two types of detection formats examined.
The position of the Hb line either before or after the three test
lines signiﬁcantly affected the pattern observed on the strips. The
Type 1 design, with the Hb line placed before the three HbA1c test
lines, showed an increased intensity at the Hb line as the % HbA1c
in blood samples increased (Fig. 1b). However, the test lines coated
with anti-HbA1c antibodies (test lines 1–3) were too pale to be
observed. We therefore presumed that when the Hb line was set
as the ﬁrst line, the assay captured most of the Hb in the blood
samples, including HbA1c. Because most of the HbA1c was cap-
tured at the ﬁrst Hb line, only a negligible amount passed through
the immunocomplexes formed on the Hb line and reached the
subsequent HbA1c test lines to immunoreact with anti-HbA1c
antibodies (monoclonal, IgG1).
However, with the Type 2 design, in which the Hb line was
placed after the three HbA1c test lines, we observed an increase in
the intensity and number of HbA1c test lines that appeared con-
comitantly with the increase in % HbA1c. The consequent satura-
tion of the binding sites at the ﬁrst test line allowed unbound
HbA1c to migrate to subsequent lines for further immunoreaction.
All of the unreacted Hb species were ﬂushed to the last line – the
Hb line – to bind with the polyclonal anti-Hb antibodies. The re-
sults of our detection format optimization studies showed that
with the type 2 design, the intensity gaps were sufﬁciently large
with increasing % HbA1c and allowed monitoring for distinct
HbA1c ranges (normal, o6.5% HbA1c; under control, 6.5% to 7.0%
HbA1c; elevated, 47.0% HbA1c). Hence, we chose the type 2 for-
mat for the simultaneous detection of HbA1c and total Hb.
3.3. Selectivity study
Because the polyclonal anti-Hb antibody (detecting antibody) –
functionalized colloidal gold binds to all Hb species (glycated or
non-glycated), it was critical to ensure that the anti-HbA1c anti-
bodies recognized only the glycation site speciﬁc to HbA1c (valine
at the N-terminal of β subunits) and transduced signal only frombound HbA1c. The HbA0 species contains the same αβ subunits
found in HbA1c (Ang et al., 2015), in which similar glycan moieties
are highly likely to be found; therefore, they could potentially
interfere with the results generated on the strip. HbA2, which
contains αδ subunits, might have glycan moieties on the α chains,
which could interfere with the signal generated if the capturing
anti-HbA1c antibodies are not speciﬁc enough.
In the selectivity studies shown in Fig. 2a, only puriﬁed HbA1c
showed responses on test lines 1–3 (on which monoclonal anti-
HbA1c antibodies were coated). HbA0 and glycated HbA0 and
HbA2 yielded no results on test lines 1–3. These observations led
us to conclude that the design of the sandwich immunoassay was
highly selective for HbA1c. Other glycation sites on Hb were not
recognized, and a “sandwich” was not formed even upon binding
and forming immunocomplexes with the polyclonal anti-Hb an-
tibody-functionalized colloidal gold.
3.4. Interference of variants
Fig. 2b shows that at the same HbA1c level (5.5% HbA1c, strip
1), the Hb line on strip 2 (tested with a sample that also contained
elevated HbF) was relatively more intense (483% higher), and test
lines 1–3 were comparatively paler (80.2% paler) than those on
strip 1. These observations agreed with those reported by Rohlﬁng
et al. (2008) for DCA 2000 (which uses an immunoturbidimetric
method) in which the presence of elevated HbF artiﬁcially lowered
the % HbA1c. HbF comprises αγ subunits in which the glycine at
the γ subunit is more readily acetylated than glycated (Rohlﬁng
et al., 2008), which suggests that the observation of lower in-
tensity on test lines 1–3 was expected, particularly when the
monoclonal anti-HbA1c antibodies used were proven to be highly
selective toward the glycation sites at valine in the N-terminus of
the β subunit. Whereas elevated HbF artiﬁcially lowered the
HbA1c level on the strip, the population of HbA constituted a re-
latively larger portion of the whole Hb population in the sample,
which contributed to the high intensity at the Hb line.
We tested three additional variants – HbH, HbE, and HbJ – with
the immunosensor. When HbJ was tested on strip 3, test lines 1–3
remained visible, but the intensity of the Hb line was lower than
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Fig. 2. (A) Four puriﬁed cross-reactants were tested on the fabricated immunosensor. (B) Variant interference study conducted with a sample of elevated HbF, HbJ, HbE, and
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similar to HbA, contains αβ chains with a mutation that adds a
negative charge to the Hb molecules, thereby affecting the accu-
racy of the cation-exchange method and resulting in artiﬁcially
low HbA1c values (Bhat et al., 2012), (Tsai et al., 2001). Our im-
munosensor, which uses highly selective monoclonal anti-HbA1c
antibodies, was partially affected by the presence of HbJ and gave a
falsely low HbA1c level.
On the contrary, compared with strips 3 (tested with HbJ) and 5
(tested with HbH), strip 4 (tested with HbE) showed a relatively
similar intensity on the Hb line. The intensities of test lines 1–3
were considerably lower than that observed on strip 1. HbE has a
mutation farther away from the N-terminal of the β chain (Little
and Roberts, 2009) that could cause a degree of structural incon-
gruence with anti-HbA1c antibodies. Similar observations were5.0
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the ﬁrst day of collection versus the signal generated at every point of the testing day.made for strip 5, which was tested with HbH. HbH has a mutation
on the α subunit. The HbA1c level measured in ratio was falsely
low and agreed with the ﬁndings of Pravatmuang et al. (2001),
who presumed that the presence of the HbH variant lowered the
HbA1c level because the polymerized β4 eluted as a non-quanti-
tating area with the HPLC method. However, we hypothesized that
the polymerization of β4 leads to structural changes that make the
glycated site on the β chain more difﬁcult to probe. All three
variants interfered with HbA1c measurement and resulted in fal-
sely low HbA1c measurements.
3.5. Blood specimen storage stability study
Fig. 3 shows that consistent signals were generated on the
strips when the same 6% HbA1c blood sample was tested over7Day 1 2 3 4
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ferences observed during the study, we performed a two-tailed t-
test comparing the results at each point of the testing to that on
day 1. No signiﬁcant difference (all t statistical values fell within
the range of the 7t critical two tail) was observed in the com-
parison of HbA1c measurements on day 1 with those on each
testing day for 7 days (Table S2a–d). Although the signal intensity
on later days was comparatively lower (Fig. 3b) than that on the
ﬁrst day of testing, the ratio of HbA1c to total Hb remained con-
stant. From the ratio obtained, we estimated % HbA1c by using the
calibration curve established, in which the % HbA1c was found to
lie within 5.2–6.2% HbA1c compared with the true value (6%
HbA1c; Fig. 3a). After storing the sample for 7 days, measurement
of % HbA1c provided a good estimation, and no false-positive re-
sults (Z6.5% HbA1c) were detected.
These observations showed that the blood sample remained
stable at 4 °C, and storage had little to no effect on the measure-
ment of % HbA1c if the test was conducted within 7 days of storage
at that temperature. Unlike Lakshmy and Gupta (2009), who re-
ported that HbA1c is stable for up to 15 days in dried blood
samples, and Rohlﬁng et al. (2012), who reported a 14-day win-
dow for HbA1c measurement when samples are stored at 4 °C
(Rohlﬁng et al., 2012), we reported on 7 days of storage at 4 °C
because it is common practice for blood samples to be kept for that
duration at UMMC before they are discarded.
3.6. Reproducibility
The coefﬁcient of variation (CV) of the lateral ﬂow im-
munosensor was found to be 6.02% in the reproducibility test (Fig.
S1). By relating the CV obtained to the physiological variance
(potential HbA1c level difference every time a measurement is
performed on the same sample), it was calculated to be 1.5%
HbA1c difference in physiological context (please refer to the de-
tailed calculation made for physiological variance in the Supple-
mentary materials). With the physiological variance measured to
be 1.5% HbA1c, the signals generated on the test strip with the
same HbA1c level are expected to be consistent and precise. On
the other hand, to relate the difference of ratiometric measure-
ment to physiological context, the calibration curve relationship
obtained Y¼0.0556Xþ0.4491 (Fig. 4) was utilized. For example,
the difference of 0.02 in ratiometric measurement would result in
a 0.2% HbA1c difference, so as 0.18–3.2% HbA1c difference (de-
tailed calculation made was presented in the Supplementary ma-
terials), indicating that a small change in ratiometric reading could
result in a signiﬁcant difference of % HbA1c in physiological con-
text. In other words, our device is reasonably sensitive, accurate
and precise in relating the ratiometric reading to physiological
change in HbA1c level and therefore its utility for personalized
medicine is justiﬁed.
Compared with the reported CVs (0.19–0.82%) of other bio-
sensors such as immunoassay microarrays (Chen et al., 2012), the
CV of our assay was higher. Nevertheless, tests with our lateral
ﬂow immunosensor can be completed more rapidly (20 min) than
those using microarray immunoassays (which require 2 h of in-
cubation), and is therefore more practical for on-site facilitation of
diabetic care. Compared with reported potentiometric methods
(Liu and Crooks, 2012), our lateral ﬂow immunosensor not only
requires less sample volume for testing (2 mL) but also has high
selectivity for HbA1c detection – without any sample pretreat-
ment. Compared with the separation matrix, our lateral ﬂow strip
requires no multistep measurement to obtain a signal for both
HbA1c and total Hb. Owing to the optimized design for simulta-
neous detection of both HbA1c and total Hb, signal measurement
can be performed in a single step with one test run. Table 1 shows
a comparison of the overall analytical performance of thedeveloped lateral ﬂow immunosensor and other biosensors.
3.7. Calibration curve
Fig. 4 shows that the linear dynamic range established with
whole blood fell within 4.5% (26 mmol mol1) to 7%
(53 mmol mol1) HbA1c, with a R2 of 0.95. This result indicates a
strong linear relationship between % HbA1c and the signal ratio
(HbA1c/total Hb) generated on the immunosensor. The small value
of the slope established with the calibration curve suggested that
the changes in HbA1c levels were subtle compared with the
consistent and constant total Hb concentration. Although the dy-
namic range of detection was narrow, the critical treatment goal
values of 6.5–7% HbA1c falling within the linear dynamic range
(4.5–7.0% HbA1c) rendered the developed lateral ﬂow im-
munosensor a useful device for diabetes care, especially for pa-
tients with poorly controlled glycemic status with HbA1c levels of
46.5% (Group, 2005) (or 47% in the United States) (ADA, 2012).
Points marked 1, 2, 3, and 4 in Fig. 4 indicate responses ob-
tained for unknown whole blood samples. Using the calibration
plot, we estimated the HbA1c level in the unknown blood samples
to be 4.6%, 4.8%, and 5.4%, and 5.8% HbA1c, whereas the Bio-Rad
Variant II HPLC measured HbA1c levels of 4.5%, 4.7%, and 6.0%, and
6.0% for sample 1, 2, 3, and 4, respectively (note: sample 3 and
4 were two different samples but both having same HbA1c level).
A two-tailed t-test for the set of measurements gave a p value of
0.79 and a t statistical value of 0.28 that fell within 72.57,
which led us to conclude that there was no signiﬁcant difference
in the HbA1c levels measured with the Bio-Rad Variant II HPLC
and our immunosensor. However, when the estimated 5.4% HbA1c
level of unknown sample 3 (N¼3) was compared to HPLC-mea-
sured value of 6.0% HbA1c, the 0.6% difference in measurement
could be a concern when it comes to diagnosing diabetes. We
believe that with further experimentation on larger sample size
(NZ30), outliers like unknown sample 3 could be addressed and
so to improve and tighten the variance between our assay and
HPLC method to a clinically relevant variance of 3–5% (Sacks et al.,
2011).
4. Conclusions
Herein we report a robust and promising lateral ﬂow HbA1c
immunosensor designed to allow HbA1c to be measured as a
Table 1
Comparison on the analytical performances of our developed HbA1c lateral ﬂow immunosensor versus other HbA1c biosensors.
HbA1c lateral ﬂow immunosensor
(this study)
Microarray immunoassay (Chen
et al., 2012)
Potentiometric method (Liu and
Crooks, 2012)
Separation matrix (McCroskey and
Melton, 2010)
Bio-recognition material Antibodies Antibodies Boronic acid Boronic acid
Sample volume required 2 μL 4 μL 50 μL 2–5 μL
Clinical testing Yes Yes No Yes
Pretreatment No No Yes No
Rapidity of test Approximately 20 min 2 hour incubation prior to test Approximately 20 min Approximately 5 min
Sensitivity NA* 0.20 ng mL1 NA NA
Reproducibility 6.02% 0.19–0.82% NA 1.7%
Linear dynamic range 4.0–7.0% HbA1c NA NA 5–16% HbA1c
* NA – Not available in the study.
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washings and single-step measurement. Because HbA1c is mea-
sured as a fraction of total Hb, we compensated for the reduction
in the immunoreaction between anti-Hb antibodies and Hb by
using the parallel reduction in HbA1c binding for stable mea-
surement of the signal ratio to calculate % HbA1c.
Good consistency was demonstrated without false-positives
when blood samples stored at 4 °C for a week were tested. Fur-
thermore, the anti-HbA1c antibodies coated at the test lines
showed high speciﬁcity and selectivity toward HbA1c when tested
against all other glycated proteins (HbA0 and glycated HbA0 and
HbA2). Moreover, we were able to distinguish samples with nor-
mal Hb from those with elevated HbF owing to high intensity at
the Hb line on the strip. However, the presence of Hb variants (HbJ,
HbE, and HbH) and elevated HbF affected the measurement of %
HbA1c. Therefore, we suggest pre-screening for the presence of
variants before performing the deﬁnitive test.
With the constructed calibration curve, quantitative measure-
ments of % HbA1c did not differ signiﬁcantly between the lateral
ﬂow immunosensor and the Bio-Rad Variant II HPLC. To improve
and expand the dynamic range of detection of % HbA1c, we will
optimize the reaction matrix of our lateral ﬂow strips in future
studies by using different types of membranes. We anticipate that
our immunosensor, developed to integrate inexpensive detection
technologies such as smartphone-based imaging, will enable rapid
point-of-care evaluation of HbA1c levels in blood samples to im-
prove on-site diabetes care.Acknowledgments
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